# Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

> **NCT02141490** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (actual)

## Conditions studied

- Prostate Cancer
- Bladder Cancer
- Kidney Cancer

## Interventions

- **DRUG:** Ferumoxytol
- **DIAGNOSTIC_TEST:** Magnetic Resonance Imaging (MRI)

## Key facts

- **NCT ID:** NCT02141490
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-15
- **Primary completion:** 2018-11-20
- **Final completion:** 2018-11-20
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141490, "Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02141490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*